Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma

Authors :: Sampsa Hautaniemi
Jan Delabie
Alejandra Cervera
Amjad Alkodsi
Leo Meriranta
Marja-Liisa Karjalainen-Lindsberg
Riku Louhimo
Rainer Lehtonen
Matias Autio
Minna Taskinen
Annika Pasanen
Sirpa Leppä
Harald Holte
Ville Rantanen
Research Programs Unit
University of Helsinki
Genome-Scale Biology (GSB) Research Program
Clinicum
Department of Oncology
Sampsa Hautaniemi / Principal Investigator
Medicum
Department of Pathology
Bioinformatics
Sirpa Marianne Leppä / Principal Investigator
HUS Comprehensive Cancer Center
Publication Year :: 2017
Publisher :: Ferrata Storti Foundation, 2017.
Abstract: Diffuse large B-cell lymphoma (DLBCL) is a group of clinically aggressive and heterogeneous malignancies, of which approximately 60% can be cured with anthracycline-based chemoimmunotherapy. Based on gene expression profiling, DLBCL can be classified into two molecularly distinct subgroups showing

Tools